{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:22:27Z","timestamp":1789986147452,"version":"4.0.1"},"reference-count":41,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30 GM114736"],"award-info":[{"award-number":["P30 GM114736"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2017.00042","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T08:22:36Z","timestamp":1491207756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient"],"prefix":"10.3389","volume":"7","author":[{"given":"Donna M.","family":"Cartledge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah L.","family":"Stabley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.","family":"Gripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Sol-Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Napper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"issue":"1","key":"B1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ajmg.c.30065","article-title":"Tumor predisposition in Costello syndrome","volume":"137C","author":"Gripp","year":"2005","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"10","key":"B2","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/ng1641","article-title":"Germline mutations in HRAS proto-oncogene cause Costello syndrome","volume":"37","author":"Aoki","year":"2005","journal-title":"Nat Genet"},{"issue":"1","key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.a.31047","article-title":"HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation","volume":"140","author":"Gripp","year":"2006","journal-title":"Am J Med Genet A"},{"issue":"20","key":"B4","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/ajmg.a.31456","article-title":"Somatic mosaicism for an HRAS mutation causes Costello syndrome","volume":"140","author":"Gripp","year":"2006","journal-title":"Am J Med Genet A"},{"issue":"8","key":"B5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/humu.20381","article-title":"Paternal bias in parental origin of HRAS mutations in Costello syndrome","volume":"27","author":"Sol-Church","year":"2006","journal-title":"Hum Mutat"},{"issue":"5","key":"B6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/jmg.2005.040352","article-title":"Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases","volume":"43","author":"Kerr","year":"2006","journal-title":"J Med Genet"},{"issue":"7","key":"B7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/gim.2013.6","article-title":"Assessing genotype-phenotype correlation in Costello syndrome using a severity score","volume":"15","author":"McCormick","year":"2013","journal-title":"Genet Med"},{"issue":"3","key":"B8","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1002\/ajmg.a.37949","article-title":"Paternal uniparental disomy with segmental loss of heterozygosity of chromosome 11 are hallmark characteristics of syndromic and sporadic embryonal rhabdomyosarcoma","volume":"170","author":"Robbins","year":"2016","journal-title":"Am J Med Genet A"},{"issue":"7","key":"B9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1183\/09031936.95.08071179","article-title":"PDE isoenzymes as targets for anti-asthma drugs","volume":"8","author":"Schudt","year":"1995","journal-title":"Eur Respir J"},{"key":"B10","first-page":"379","article-title":"Zardaverine: a cyclic AMP specific PDE III\/IV inhibitor","volume":"34","author":"Schudt","year":"1991","journal-title":"Agents Actions Suppl"},{"key":"B11","doi-asserted-by":"publisher","first-page":"Aendix3B","DOI":"10.1002\/0471142735.ima03bs21","article-title":"Trypan blue exclusion test of cell viability","volume":"Appendix 3","author":"Strober","year":"2001","journal-title":"Curr Protoc Immunol"},{"issue":"2","key":"B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"issue":"3","key":"B13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/sj.bjp.0706341","article-title":"Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures","volume":"146","author":"Wang","year":"2005","journal-title":"Br J Pharmacol"},{"issue":"12","key":"B14","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.str.2004.10.004","article-title":"Structural basis for the activity of drugs that inhibit phosphodiesterases","volume":"12","author":"Card","year":"2004","journal-title":"Structure"},{"issue":"5","key":"B15","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/j.1476-5381.1996.tb15522.x","article-title":"The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4","volume":"118","author":"Hughes","year":"1996","journal-title":"Br J Pharmacol"},{"issue":"19","key":"B16","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/0024-3205(82)90095-9","article-title":"HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro","volume":"31","author":"Ruppert","year":"1982","journal-title":"Life Sci"},{"issue":"11","key":"B17","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1021\/jm00037a021","article-title":"Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues","volume":"37","author":"Ashton","year":"1994","journal-title":"J Med Chem"},{"issue":"1","key":"B18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3565(24)38895-0","article-title":"A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity","volume":"295","author":"Aoki","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"B19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-3565(25)31785-4","article-title":"Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation","volume":"211","author":"Hidaka","year":"1979","journal-title":"J Pharmacol Exp Ther"},{"key":"B20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0065-7743(08)60732-0","article-title":"Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents","volume":"29","author":"Christensen","year":"1994","journal-title":"Annu Rep Med Chem"},{"issue":"1","key":"B21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0922-4106(94)90125-2","article-title":"Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors","volume":"268","author":"Tang","year":"1994","journal-title":"Eur J Pharmacol"},{"issue":"Pt 2","key":"B22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1042\/bj2910389","article-title":"Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase","volume":"291","author":"Souness","year":"1993","journal-title":"Biochem J"},{"issue":"15","key":"B23","doi-asserted-by":"publisher","first-page":"8991","DOI":"10.1073\/pnas.95.15.8991","article-title":"Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase","volume":"95","author":"Soderling","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 2","key":"B24","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1046\/j.1463-1326.2002.0040s2s14.x","article-title":"The pharmacology of cilostazol","volume":"4","author":"Schror","year":"2002","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"B25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0026-895X(25)10513-0","article-title":"Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3","volume":"48","author":"Alvarez","year":"1995","journal-title":"Mol Pharmacol"},{"issue":"2","key":"B26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0006-8993(89)91669-7","article-title":"Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram","volume":"503","author":"Kaulen","year":"1989","journal-title":"Brain Res"},{"issue":"5","key":"B27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/1087057106288048","article-title":"Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model","volume":"11","author":"Fryknas","year":"2006","journal-title":"J Biomol Screen"},{"issue":"D1","key":"B28","doi-asserted-by":"publisher","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","article-title":"PubChem substance and compound databases","volume":"44","author":"Kim","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B29","author":"National Center for Biotechnology Information","year":"2016","journal-title":"PubChem BioAssay Database AID=1117347"},{"key":"B30","author":"National Center for Biotechnology Information","year":"2016","journal-title":"PubChem BioAssay Database AID=720692"},{"issue":"52","key":"B31","doi-asserted-by":"publisher","first-page":"34970","DOI":"10.1074\/jbc.273.52.34970","article-title":"Generation of destabilized green fluorescent protein transcription reporter","volume":"273","author":"Li","year":"1998","journal-title":"J Biol Chem"},{"issue":"3","key":"B32","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2144\/00293rr02","article-title":"Development of a destabilized firefly luciferase enzyme for measurement of gene expression","volume":"29","author":"Leclerc","year":"2000","journal-title":"Biotechniques"},{"issue":"11","key":"B33","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1021\/cb3002478","article-title":"Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate","volume":"7","author":"Hall","year":"2012","journal-title":"ACS Chem Biol"},{"issue":"20","key":"B34","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/Nejm198805193182002","article-title":"Anagrelide \u2013 a new drug for treating thrombocytosis","volume":"318","author":"Silverstein","year":"1988","journal-title":"N Engl J Med"},{"issue":"1","key":"B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","article-title":"Anagrelide, a therapy for thrombocythemic states \u2013 experience in 577 patients","volume":"92","author":"Silverstein","year":"1992","journal-title":"Am J Med"},{"issue":"4","key":"B36","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"B37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/cancers6010436","article-title":"The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment","volume":"6","author":"Fajardo","year":"2014","journal-title":"Cancers (Basel)"},{"issue":"3","key":"B38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"2","key":"B39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nchembio.1984","article-title":"Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics","volume":"12","author":"de Waal","year":"2016","journal-title":"Nat Chem Biol"},{"issue":"3","key":"B40","doi-asserted-by":"publisher","first-page":"e90627","DOI":"10.1371\/journal.pone.0090627","article-title":"Phosphodiesterase 3\/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"B41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajmg.10241","article-title":"Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol","volume":"108","author":"Gripp","year":"2002","journal-title":"Am J Med Genet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00042\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T20:22:54Z","timestamp":1750191774000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00042\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":41,"URL":"https:\/\/doi.org\/10.3389\/fonc.2017.00042","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,3]]}}}